The purpose of this pilot study is to provide data on the feasibility of conducting a large
clinical trial on the polypill (combination of aspirin, angiotensin converting enzyme
inhibitor, thiazide diuretic, and statin) for primary prevention of cardiovascular disease
(CVD). We hypothesized that A "polypill" comprising the aforementioned four components would
significantly reduce the estimated 10-year total CVD risk score with high adherence and no
significant increase in adverse effects compared to the standard practice.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest School of Medicine Wake Forest University Health Sciences
Collaborators:
National Hospital of Sri Lanka World Health Organization